Infliximab in inflammatory bowel disease

• Auteurs principaux: Konstantinos Papamichael (Auteur), Steve Lin (Auteur), Matthew Moore (Auteur), Garyfallia Papaioannou (Auteur), Lindsey Sattler (Auteur), Adam S. Cheifetz (Auteur)
• Format: Livre
• Publié: SAGE Publishing, 2019-03-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large...